J Goodwin to Prostate-Specific Antigen
This is a "connection" page, showing publications J Goodwin has written about Prostate-Specific Antigen.
Connection Strength
2.404
-
Goodwin JS, Sheffield K, Li S, Tan A. Receipt of Cancer Screening Is a Predictor of Life Expectancy. J Gen Intern Med. 2016 11; 31(11):1308-1314.
Score: 0.469
-
Zanwar P, Lin YL, Kuo YF, Goodwin JS. Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study. BMC Health Serv Res. 2016 Jan 15; 16:17.
Score: 0.444
-
Goodwin JS, Jaramillo E, Yang L, Kuo YF, Tan A. Is anyone listening? Variation in PSA screening among providers for men 75+ before and after United States Preventive Services Task Force recommendations against it: a retrospective cohort study. PLoS One. 2014; 9(9):e107352.
Score: 0.404
-
Jaramillo E, Tan A, Yang L, Kuo YF, Goodwin JS. Variation among primary care physicians in prostate-specific antigen screening of older men. JAMA. 2013 Oct 16; 310(15):1622-4.
Score: 0.380
-
Goodwin JS, Tan A, Jaramillo E, Kuo YF. Prostate-specific antigen testing in men aged 40-64 years: impact of publication of clinical trials. J Natl Cancer Inst. 2013 May 15; 105(10):743-5.
Score: 0.364
-
Howrey BT, Kuo YF, Lin YL, Goodwin JS. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol A Biol Sci Med Sci. 2013 Jan; 68(1):56-61.
Score: 0.343